Peptides›Other›Octreotide

Octreotide

/ Synthetic cyclic octapeptide analog of somatostatin; SSTR2/SSTR5 agonist

TIER 1 · ClinicalN = 0 · TESTING PENDINGLAST REVIEW 2026·04·20

ALIAS · Sandostatin · Sandostatin LAR

—

Pass rate

Samples

Suppliers

Research use onlyAny dose figures below describe what specific cited studies used, reported factually. Nothing on this page is guidance for human use.READ FIRST →

Terms in this page you can click for a plain-English popup: , , , , , , , .

§ A · Identity

Primary sequence— sequence not captured —

MW · —CLASS · Synthetic cyclic octapeptide analog of somatostatin; SSTR2/SSTR5 agonistCATEGORY · Other

FDA-approved (Sandostatin, 1988) for acromegaly, carcinoid syndrome, and VIPoma. Long-acting release (LAR) formulation provides once-monthly dosing.

§ B · Mechanism of action

Octreotide is a synthetic cyclic octapeptide analog of somatostatin with preferential affinity for SSTR2 and SSTR5 receptors. It inhibits GH release (used in acromegaly), serotonin and vasoactive intestinal peptide secretion (used in carcinoid syndrome and VIPoma), and has broader effects on gastrointestinal hormone secretion.

§ C · Human clinical evidence

Extensive clinical history since 1988 approval. Standard of care for medical therapy of acromegaly, symptomatic management of carcinoid syndrome, and hormone-secreting neuroendocrine tumors.

§ D · Primary literature

PubMed19704057Rinke A et al. — Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors · Journal of Clinical Oncology · human-phase-3-rctOctreotide LAR prolonged time to tumor progression versus placebo in metastatic midgut NET (HR 0.34); first RCT-grade evidence for somatostatin analog antitumor activity.Limitations: Small n; midgut NETs only.2009

PubMed24423301Caron PJ et al. — Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly · The Journal of Clinical Endocrinology and Metabolism · human-phase-3-rctLong-acting somatostatin analog produced significant tumor shrinkage as primary therapy in treatment-naive acromegaly.Limitations: Lanreotide-arm trial cited for class effect; octreotide LAR shows similar pattern.2014

§ F · Safety signal

Common: gastrointestinal AEs (diarrhea, abdominal pain, steatorrhea), gallstone formation with chronic use (10-20% over years), glucose intolerance or hypoglycemia. Bradycardia at higher doses.

§ H · Regulatory status

Regulatory status

FDA status:: FDA-approved
Compounding:: Not eligible for compounding (approved, not in shortage)